IgM Test · Blood

Your body has several types of antibodies, but one of them always shows up first. When your immune system meets a new virus, bacterium, or other invader, IgM (immunoglobulin M) is the initial antibody it deploys. Measuring your total serum IgM tells you something fundamental about the strength and readiness of your immune system's first line of defense.

This test is not part of a standard metabolic panel or CBC. If your routine bloodwork looks fine, you still have no idea whether your IgM is adequate. That matters because persistently low IgM has been linked to higher infection risk, worse outcomes in critical illness, and even greater cardiovascular vulnerability. A single number can tell you whether your immune system's alarm system is properly armed.

What IgM Does in Your Body

IgM is produced by a type of white blood cell called a B cell (also known as a B lymphocyte). It circulates in your blood as a large, star-shaped cluster of five antibody units joined together, which gives it exceptional ability to latch onto invaders and flag them for destruction. Because of this structure, IgM is especially effective at activating complement, a cascade of proteins that punch holes in bacteria and infected cells.

Beyond fighting acute infections, your body also produces "natural" IgM constantly, even without a specific infection trigger. These natural IgM antibodies are made by a specialized subset of B cells (called B1 cells) and play a housekeeping role: they bind to damaged cells, oxidized fats, and cellular debris, helping your body clear waste before it triggers chronic inflammation.

Heart Disease and Atherosclerosis

One of the more surprising findings about IgM involves heart health. Natural IgM antibodies that target oxidized LDL (the damaged form of "bad" cholesterol that accumulates in artery walls) appear to be protective against coronary heart disease. These are measured by a specialized research test for IgM anti-MDA-LDL, which is different from the total IgM test described here. In a nested case-control study within the NORDIL hypertension trial, which followed 10,881 adults with high blood pressure for a median of 4.5 years, people with higher levels of IgM antibodies against a specific type of oxidized LDL (called MDA-LDL) had roughly 70% lower odds of developing coronary heart disease compared to those with lower levels.

That same research, combined with imaging data from the IBIS-3 study of 143 patients with known coronary artery disease, showed that higher IgM anti-MDA-LDL levels were linked to smaller necrotic cores (the unstable, rupture-prone centers of arterial plaques) and less lipid-rich plaque overall. Multiple cohorts studying people with chronic kidney disease, dialysis patients, and hypertensive adults have found similar patterns: lower levels of these specific protective IgM subtypes correlate with worse cardiovascular outcomes.

A standard total IgM test does not directly measure these protective IgM anti-MDA-LDL antibodies, so a low total IgM does not automatically mean your arteries are in trouble. Still, total IgM reflects the broader pool from which these protective antibodies are drawn. Combined with other cardiovascular risk markers like ApoB, hs-CRP (high-sensitivity C-reactive protein, a measure of inflammation), and Lp(a) (lipoprotein(a), an inherited cholesterol particle), your IgM level adds context about your body's immune-mediated defenses against the oxidized lipids that drive plaque formation.

Immune Deficiency and Infection Risk

Persistently low total IgM can signal an immune system that is not producing enough of its frontline antibodies. Selective IgM deficiency, where IgM is low but other antibodies like IgG and IgA are normal, is increasingly recognized as more than a curiosity. It is associated with recurrent infections, especially from encapsulated bacteria (bacteria with a protective outer coating, such as Streptococcus pneumoniae), autoimmune conditions, blood cell disorders, and allergic disease. In pediatric populations, about a quarter of children with selective IgM deficiency have an identifiable genetic immune disorder.

IgM memory B cells depend heavily on the spleen. People who have had their spleen removed or who have conditions that impair spleen function are at particular risk for dangerous infections from encapsulated bacteria, precisely because they lose the IgM-producing cells that provide early protection.

IgM and Blood Cancers

A very high IgM, especially when it comes from a single clone of B cells (called a monoclonal spike), points toward a blood cancer or pre-cancerous state. Waldenstrom macroglobulinemia is a slow-growing lymphoma defined by monoclonal IgM production. It can cause hyperviscosity (blood that is too thick to flow properly), bleeding, nerve damage, and acquired clotting problems. Very high monoclonal IgM is strongly associated with low levels of von Willebrand factor (a clotting protein), and bleeding risk improves as IgM comes down with treatment.

A smaller monoclonal IgM spike that does not yet cause symptoms is called IgM MGUS (monoclonal gammopathy of undetermined significance). This is not cancer, but it carries a lifelong risk of progression: roughly 55% of people with a high monoclonal IgM protein and an abnormal free light-chain ratio will progress to lymphoma or Waldenstrom macroglobulinemia within 20 years. Anyone with a monoclonal IgM spike needs long-term monitoring.

Aging and Longevity

In a study of Chinese centenarians, very low serum IgM (below 0.708 g/L, or roughly 70.8 mg/dL) was independently associated with about 36% higher all-cause mortality over approximately 30 months. This suggests IgM may serve as a marker of immune aging, reflecting the gradual decline in the body's ability to mount early immune responses. While no one is suggesting IgM is a longevity drug target, tracking it over time may offer a window into how well your immune system is holding up as you age.

Reference Ranges

Total serum IgM is reported in milligrams per deciliter (mg/dL). Standard adult reference ranges vary somewhat by lab and assay method, but most clinical laboratories use ranges in the neighborhood of 40 to 230 mg/dL for adults. Women tend to have slightly higher IgM than men. Values shift with age: children have different ranges, and IgM may gradually decline in older adults as part of immune aging.

These ranges come from large population distributions and represent the central 95% of healthy adults. They are not outcome-based thresholds like the risk tiers used for LDL cholesterol or HbA1c. No guideline body has published "optimal" versus "elevated" IgM tiers tied to hard clinical outcomes. Instead, interpretation depends on context.

Always compare your results within the same lab over time. Different assays and instruments can produce slightly different numbers for the same sample.

When Results Can Be Misleading

IgM has relatively low within-person biological variability in healthy adults, with natural fluctuations (intra-individual coefficient of variation) of around 6 to 10%. However, a few situations can distort a single reading.

• Recent or active infection: Any new infection triggers a transient IgM spike that peaks around 2 to 5 weeks and fades over the following month or two. A blood draw during this window will show elevated IgM that does not reflect your baseline immune status.
• Rituximab and similar B cell depleting drugs: Rituximab (a medication that destroys B cells, used for autoimmune diseases and certain cancers) can cause persistent IgM suppression that outlasts its effects on other antibody types and even persists after B cell counts recover. If you have been treated with rituximab or a similar drug, your IgM may be artificially low for months to years.
• Clozapine: This antipsychotic medication has been shown to progressively lower IgM over 12 to 24 weeks of treatment, as part of a broader pattern of reduced antibody production.
• Changes of less than 20 to 30%: Given combined analytical and biological variation, changes in IgM smaller than roughly 20 to 30% between draws may fall within normal fluctuation and should not drive clinical decisions on their own.

Tracking Your Trend

A single IgM reading is a snapshot. What matters more is your trajectory. Because IgM has strong "individuality" (your personal baseline may be consistently at the low or high end of the reference range), establishing your own number and watching it over time is far more informative than comparing one result to a population average.

Get a baseline measurement when you are healthy, not recovering from an illness or recent vaccination. If you are making changes that might affect your immune system (starting or stopping immunosuppressive medications, for example), retest in 3 to 6 months. Otherwise, annual monitoring is reasonable. A steady decline over multiple readings is more concerning than a single low value, particularly if you are over 60, have autoimmune disease, or have been treated with B cell depleting therapies.

What to Do With an Abnormal Result

If your IgM comes back low, the first step is to repeat it on a separate occasion when you are feeling well and not taking any new medications. If it is confirmed low, order a full immunoglobulin panel (IgG, IgA, and IgM together) and a complete blood count with differential to check for abnormalities in your white blood cells. A protein electrophoresis test can help determine whether a high IgM is polyclonal (from many different B cell clones, suggesting infection or autoimmunity) or monoclonal (from a single clone, suggesting MGUS or lymphoma).

Persistently low IgM with recurrent infections warrants evaluation by an immunologist. A monoclonal IgM spike, even a small one, should be evaluated by a hematologist, because the lifetime progression risk is real and early monitoring allows for timely intervention. If your IgM is in the normal range but trending downward over time, continue tracking and consider whether medications, aging, or an emerging immune condition might be contributing.